Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) closed at $8.72 in the last session, up 5.19% from day before closing price of $8.29. In other words, the price has increased by $5.19 from its previous closing price. On the day, 1.18 million shares were traded. ARCT stock price reached its highest trading level at $8.78 during the session, while it also had its lowest trading level at $7.93.
Ratios:
We take a closer look at ARCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
On October 23, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARCT now has a Market Capitalization of 236787488 and an Enterprise Value of 67284496. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.16 while its Price-to-Book (P/B) ratio in mrq is 1.02. Its current Enterprise Value per Revenue stands at 0.551 whereas that against EBITDA is -0.971.
Stock Price History:
The Beta on a monthly basis for ARCT is 2.10, which has changed by -0.5719195 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, ARCT has reached a high of $24.17, while it has fallen to a 52-week low of $8.04. The 50-Day Moving Average of the stock is -48.95%, while the 200-Day Moving Average is calculated to be -40.08%.
Shares Statistics:
According to the various share statistics, ARCT traded on average about 1.23M shares per day over the past 3-months and 1365460 shares per day over the past 10 days. A total of 27.15M shares are outstanding, with a floating share count of 24.87M. Insiders hold about 8.42% of the company’s shares, while institutions hold 96.39% stake in the company. Shares short for ARCT as of 1760486400 were 5310305 with a Short Ratio of 4.33, compared to 1757894400 on 5947408. Therefore, it implies a Short% of Shares Outstanding of 5310305 and a Short% of Float of 30.23.
Earnings Estimates
The dynamic stock of Arcturus Therapeutics Holdings Inc (ARCT) is currently attracting attention from 9.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.12 and low estimates of -$1.88.
Analysts are recommending an EPS of between -$1.04 and -$4.42 for the fiscal current year, implying an average EPS of -$2.63. EPS for the following year is -$2.35, with 9.0 analysts recommending between $1.41 and -$4.91.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for ARCT’s current fiscal year. The highest revenue estimate was $116.18M, while the lowest revenue estimate was $57.68M, resulting in an average revenue estimate of $88.28M. In the same quarter a year ago, actual revenue was $152.31MBased on 11 analysts’ estimates, the company’s revenue will be $94.63M in the next fiscal year. The high estimate is $279.39M and the low estimate is $14.6M.
